FDA approves expanded indication for UCB’s Briviact to treat pediatric patients

[cafead]

via The US Food and Drug Administration (FDA) has approved an expanded indication for UCB’s Briviact (brivaracetam) CV as monotherapy or adjunctive therapy for the treatment of partial-onset seizures in paediatric patients aged one month and above.

article source